SK Biopharmaceuticals and Arvelle Therapeutics Announce Agreement to Develop and Commercialize Cenobamate in Europe

Arvelle Therapeutics to receive rights to develop and commercialize cenobamate, an investigational antiepileptic drug developed by SK Biopharmaceuticals, in Europe

SK Biopharmaceuticals to receive upfront payment of $100 million and will be eligible for... Biopharmaceuticals, Licensing SK Biopharmaceuticals, Arvelle Therapeutics, cenobamate

Source: HSMN NewsFeed - February 14, 2019 Category: Pharmaceuticals Source Type: news